Bristol-Myers Squibb preclinical data

BMY's Pharmaceutical Research Institute in Seattle published successful treatment of the disease in a mouse model, using a protein that interrupts a signal needed to activate antigen-specific T cells.

The fusion antibody blocked formation of auto-antibodies and prolonged life in mice that develop a lupus-like condition. The treatment worked even when it was given only in the most advanced stage of the disease. ...